<DOC>
	<DOCNO>NCT00079053</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes necessary growth . Giving erlotinib chemoradiotherapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose adjuvant erlotinib give complete chemoradiotherapy treat patient locally advance squamous cell carcinoma ( cancer ) head neck .</brief_summary>
	<brief_title>Adjuvant Erlotinib After Completing Chemoradiotherapy Treating Patients With Locally Advanced Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine recommend dose adjuvant erlotinib completion chemoradiotherapy patient stage III , IVA , IVB squamous cell carcinoma head neck . - Determine toxicity drug patient . - Determine effect drug plasma urinary angiogenic factor ( specifically vascular endothelial growth factor receptor [ VEGFR ] , VEGFR1 , VEGFR2 , basic fibroblast growth factor level ) patient . - Compare disease-free survival patient treat drug chemoradiotherapy vs historical control patient treat chemoradiotherapy alone . - Correlate level angiogenic factor initial blood vessel concentration tumor presence absence EGFRvIII mutation patient treat drug . OUTLINE : This open-label , dose-escalation , multicenter study . Patients receive oral erlotinib daily day 1-28 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos erlotinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional 8 patient treat dose level . Patients follow 4 week , every 12 week 3 year , annually thereafter . PROJECTED ACCRUAL : A total 6-20 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck Stage III , IVA , IVB Must complete cisplatin carboplatinbased chemoradiotherapy within past 412 week Prior radiotherapy must give radical intent receipt least 90 % plan dose No evidence disease presence inoperable minimal residual disease , define 1 following : Complete response primary tumor site node ( without nodal surgery chemoradiotherapy ) Negative lymph node status ( physical radiological exam ) AND persistent tumefaction le 25 % original tumor size residual mass due scar Tumor tissue sample available EGFRvIII mutation analysis No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic ALT/AST &lt; 2 time upper limit normal ( ULN ) Bilirubin &lt; ULN ( unless due Gilbert 's syndrome ) Renal Creatinine &lt; 1.5 time ULN Cardiovascular No myocardial infarction within past year No cardiac ventricular arrhythmia require medication No history cardiac disease No uncontrolled high blood pressure No unstable angina No congestive heart failure Ophthalmic No history severe dry eye syndrome , Sjögren 's syndrome , keratoconjunctivitis sicca No severe exposure keratopathy No abnormal slitlamp examination use vital dye ( e.g. , fluorescein BengalRose ) No abnormal corneal sensitivity test ( Schirmer test similar tear production test ) No disorder might increase risk epitheliumrelated complication ( e.g. , bullous keratopathy , aniridia , severe chemical burn , neutrophilic keratitis ) No congenital abnormality ( e.g. , Fuch 's dystrophy ) No ocular inflammation infection Gastrointestinal Able take oral medication No gastrointestinal ( GI ) tract disease require IV alimentation No uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease ulcerative colitis ) No active peptic ulcer disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious active infection No serious underlie medical condition would preclude study participation No prior allergic reaction compound similar chemical biological composition erlotinib No malignancy past 5 year except adequately treat nonmelanoma skin cancer ( unless area treat radical radiotherapy ) carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Recovered prior chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics Recovered prior radiotherapy Surgery See Disease Characteristics No prior surgical procedure affect absorption No concurrent ophthalmic surgery Other More 4 week since prior investigational drug No concurrent investigational agent No concurrent anticancer therapy Concurrent oral anticoagulant ( e.g. , warfarin ) allow provide increased vigilance respect INR Concurrent nasogastric gastrostomy tube feed dysphagia allow provide evidence significant residual mucositis ( i.e. , &gt; grade 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
</DOC>